Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (265)	12/2/1997 2:21:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 353

....and you discovered hot water, the biggest discovery after Newton stoped sleeping under apple three... mz

To: JOHN W. who wrote (265)	12/2/1997 3:01:00 PM
From: Douglas Nordgren	Respond to of 353

Chiron Grants Bristol-Myers Squibb and Arris First Non-Exclusive HCV Licences Hepatitis C Virus Patent Portfolio Rights to be Used for Protease Inhibitor Research biz.yahoo.com EMERYVILLE, Calif.--(BW HealthWire)--Dec. 1, 1997--Chiron Corporation (NASDAQ:CHIR - news) announced today that it has granted to Bristol-Myers Squibb Company and Arris Pharmaceutical Corporation the first non-exclusive licenses under the company's hepatitis C virus (HCV) patent portfolio for protease inhibitor research. These licenses allow the two companies to practice under Chiron's patents with respect to the use of HCV NS3 protease in protease inhibitor research activities. ''We believe these are the first of many license agreements since there is intense interest in developing potential protease inhibitor therapeutics to treat HCV,'' stated Ed Penhoet, Ph.D., Chiron's president and chief executive officer. ''For a reasonable period of time, we will continue to make our patent estate available to companies working to discover drugs for this serious disease. At the same time, we will pursue our own research and product development activities for hepatitis.'' Chiron has been actively involved in non-A, non-B hepatitis research since the early 1980's, and is a recognized scientific leader in the field of hepatitis. As a result of Chiron's successful cloning of HCV, Chiron possesses an extensive HCV patent portfolio, and is engaged in numerous research and commercial activities which utilize Chiron's expertise in the HCV field. Chiron Corporation, headquartered in Emeryville, California, is a science-driven, market-directed healthcare company that combines diagnostic, vaccine and therapeutic strategies to control diseases such as AIDS, hepatitis, cardiovascular disease and cancers in which Chiron has a core expertise. Contact: Chiron Corporation, Emeryville Jim Knighton, 510/923-6055 (VP, Investor Relations)